The Wistar Institute’s David B. Weiner, Ph.D. -; Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research -; and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.
New immune therapy improves survival and reduces tumor burden in glioblastoma
- Post author:
- Post published:December 3, 2024
- Post category:uncategorized